[Poly (ADP-ribose) polymerase inhibitor combination therapy in metastatic castration-resistant prostate cancer]
{{output}}
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic challenge. Poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) combined with new hormonal agents (NHA) offer novel treatment o... ...
